Thursday, February 25, 2010
Some Openings at Industry
Integral Molecular is a platform-based biotechnology company, originally spun out of the University of Pennsylvania. Integral Molecular provides innovative solutions for scientific research and drug discovery applications involving integral membrane proteins, such as GPCRs and ion channels. Integral Molecular has full-time positions open immediately for qualified Ph.D.-level scientists. In addition to helping commercialize Integral's products, you will be involved in projects that are expected to result in a number of research publications.
Interested applicants should email their resume in Word format to careers@integralmolecular.com with the specific 'Job ID#' in the Subject line.
Job #100115, Cell Biologist: This Ph.D.-level position involves signal transduction research downstream of cell surface receptor activation in cells. The candidate will have a background in signal transduction and extensive experience working with cells and cellular functions, preferably involving GPCRs. Experience with DNA transfection, immunofluorescence, and fluorescence-based cellular assays is desired. Knowledge of protein structure-function analysis and protein structure visualization is a plus. The candidate should have excellent organization skills and work well in a team setting. A Ph.D. with 0-2 years experience or post-doc experience is required.
Job #100116, Biochemist: This Ph.D.-level position involves assay development assessing the function of enzymatic proteins interacting with their partner molecules. The candidate will have experience with protein enzymology or signal transduction and will have relevant experience in protein expression, protein folding, and the assessment of protein activity. Experience with GPCRs, ion channels, or membrane biochemistry is a plus. The candidate should be highly inquisitive, have excellent attention to detail, and demonstrated ability to address challenging scientific questions. A Ph.D. with 0-2 years experience or post-doc experience is required.
Job #091010, Molecular Biology Scientist: This position will involve working at a biotechnology company with a dedicated group of scientists on the development and commercialization of biomedical technology-based products. Projects will involve conducting and coordinating DNA cloning projects that are central to all of the work in the company. Applicants must be proficient in state of the art technologies employed for recombinant DNA manipulation with the goal of optimizing expression in eukaryotic cells. You will also be responsible for organizing stocks of DNA, bacteria, and electronic maps. Familiarity with skills in generating chimeric recombinant sequences, site-directed mutagenesis, random mutagenesis, codon optimization, and/or gene synthesis is desired. Specific experience with manipulation of unstable sequences or toxic proteins (e.g. viral genomes) is also desired. Familiarity with common molecular biology software applications is essential. Candidates should have a Ph.D. and at least 4 years of relevant experience. Candidates with M.S. or B.A./B.S. degrees and extensive experience may also be considered. Experience and training in the fields of Molecular Biology, Molecular Virology, Genetic Engineering, and Gene Therapy may be relevant for this position. The candidate must be attentive to detail and capable of effective communication, including presenting at team/company meetings and interacting with other teams of scientists that will rely on your work.
*********************************************************************
American Association for Cancer Research, Inc.
External Position Notice
Date Posted: February 24, 2010
Deadline for Applying: Open until filled
Position Title: Program Administrator - Scientist
Reports to: Director of Program Development
Department: Program Development
Employment Status: Full-time/Exempt
Position Description and Responsibilities
a. Responsible for working on three to four meetings per year, possibly more.
b. Coordinates grant applications for some conferences and workshops.
c. Develops brochures.
d. Collaborates with Director of Program Development.
e. Communicates with Program Committee chairs and members.
f. Works with Program chairs to determine nature and scope of assigned programs.
g. Collaborates with the Meetings and Exhibits Department on the coordination of logistics and scheduling of assigned meetings.
h. Works with Marketing Department to create and develop promotional materials for assigned meetings.
i. Assists with activities related to special conferences and workshops.
j. Assists Director of Program Development with committee responsibilities.
Position Requirements
BA Degree required. Advanced degree preferred. Science background strongly preferred.
Minimum of 5 years' program development and administration experience in the areas of scientific meetings, conferences and workshops.
Excellent writing and verbal communication skills.
Ability to travel and attend one to two meetings per year.
Ability to communicate and interact with all levels of people, particularly scientists.
Excellent interpersonal skills.
Ability to write grants for various conferences and workshops (grant applications and reports).
Microsoft Word proficiency.
Knowledge of Lotus Notes.
Experience in creating reports using Excel and Access databases.
How to Apply: Please submit your cover letter and resume (including salary history) to:
Human Resources
P.O. Box 40138
Philadelphia, PA 19106
humanresources@aacr.org
Fax: (215) 440-1045
Jobs at Children's Hospital of Philadelphia
The Center for Cellular and Molecular Therapeutics, Stem Cell Core Facility
Position: Research Technician/Postdoctorial Associate
Description: We are seeking a highly motivated individual who is interested in working in the area of Embryonic Stem Cell (ESC) and Inducible Pluripotent Stem Cell (IPSC) biology. This position will involve in vitro differentiation of ESCs and IPSCs into endoderm progenitors for further characterization and analysis. Candidate should be organized, good at problem solving, and possess the ability to design and implement experiments independently. A successful applicant should have hands-on experience in tissue cell culture, and a strong background in molecular biology. Prior experience working with embryonic stem cells is preferred, but no required.
Send or e-mail your application letter and C.V. to:
Dr. Paul Gadue, Center for Cellular and Molecular Therapeutics
The Children's Hospital of Philadelphia
3501 Civic Center Blvd, Room 5012
Philadelphia, Pa 19104
e-mail: gaduep@email.chop.edu
Mouse Genetics 2011
• Disease Models
• Large Scale Resources
• Preclinical Translation
• System Genetics
• and more!
Hear from featured keynote speaker Francis S. Collins, Director, National Institutes of Health as he describes his vision for the future of biomedical research and the role mouse research will have in improving human health.
Mark your calendars now to be in Washington, DC for this important conference June 22-26, 2011. Visit the website for updates and sponsorship opportunities.
Saturday, February 20, 2010
Sanofi-Aventis enters French research partnership
Besides Genentech and UC San Francisco, French drugmaker Sanofi-Aventis said Wednesday it has formed a research partnership with France's National Alliance for Life Sciences and Healthcare to boost research in areas such as aging, infectious diseases and regenerative medicine.
The drugmaker also entered a corporate sponsorship agreement to provide an annual allowance that supports researchers who set up their labs in France. Sanofi has pledged to invest as much as 50 million euros (about $68 million) in the partnerships over five years.
The National Alliance includes the French Atomic Energy Commission, the National Centre for Scientific Research and the National Institute of Health and Medical Research, among other agencies.
Big drugmakers have turned more to partnerships or acquisitions in recent years to help defray research costs and develop a steady stream of new drug possibilities.
Sources: AP and Sanofi-aventis
UCSF enters drug discovery agreement with Genentech
The University of California, San Francisco has signed a partnership agreement with Genentech, Inc., a wholly owned member of the Roche Group, to discover and develop drug candidates for neurodegenerative diseases.
Through the agreement, Genentech will provide funding and its research acumen in neuroscience and will collaborate with UCSF to identify small molecules.
Genentech will support the work of several researchers at the UCSF Small Molecule Discovery Center (SMDC), which is administered by the UCSF School of Pharmacy and located in the California Institute for Quantitative Biosciences (QB3) on the UCSF Mission Bay campus. A research team at Genentech will work closely with UCSF to develop a drug candidate based on prior academic research conducted at the SMDC and discoveries at Genentech.
In addition to receiving financial support from Genentech for its research function, UCSF has the potential for further funding in excess of $13 million, if certain development and commercial milestones are met, plus royalties.
This is the first major collaboration the SMDC has formed with an industry partner, according to Jim Wells, PhD, who founded the center in 2005 and serves as its director. Wells and the center’s associate directors – Adam Renslo, PhD, and Michelle Arkin, PhD – will lead the project in collaboration with the Genentech team.
“What is transformative about this agreement from the University’s perspective is that it is a true collaboration between UCSF and Genentech scientists with the intent to generate drug candidates. This is different from a standard out-license or simple research collaboration,” said Wells, who is also chair of the Department of Pharmaceutical Chemistry in the UCSF School of Pharmacy and a faculty affiliate of QB3.
“Finding targeted compounds is a major obstacle in the drug discovery process, in part because most academic researchers don’t have access to this type of facility,” Wells said. “This collaboration shows how a center like the SMDC can help support the path from new biology into therapeutic products to help improve patients’ lives.”
This collaboration builds upon the existing master agreement between Genentech and UCSF, which allows the two to collaborate in a streamlined manner.
“We are very pleased to enter this agreement and are hopeful that together we can develop new treatments to help people with neurodegenerative diseases,” said Marc Tessier-Lavigne, PhD, executive vice president, research and chief scientific officer of Genentech. “To date we have entered into more than 15 research collaborations with UCSF, across several therapeutic areas. We believe that this latest agreement with SMDC enhances our relationship with the University and creates a new model for important industry-academic drug development partnerships.”
The partnership also coincides with the UCSF School of Pharmacy’s goal of shaping the future of pharmacy science by working in fresh, collaborative ways, according to Mary Anne Koda-Kimble, PharmD, dean of the UCSF School of Pharmacy.
“This is a tremendous new partnership and one that fits perfectly with one of the school’s major strategic goals,” Koda-Kimble said. “Our work with QB3 is a great example of how we are doing this. We believe the new UCSF partnership with Genentech takes this to a whole new level.”
The SMDC offers all UC biomedical researchers access to modern small-molecule discovery technologies, including high-throughput screening and follow-up medicinal chemistry. The center performs biochemical and cell-based assays using liquid handling robots and a screening library of more than 180,000 compounds. It also houses a group of medicinal chemistry researchers who optimize screening hits into drug leads. Over the past four years, the center has grown to 18 biologists and chemists, many with pharmaceutical experience.
The center is based on high-throughput screening, medicinal chemistry, and fragment-based screening, including a novel approach called “Tethering,” which Wells pioneered in his previous role as founder, president, and chief scientific officer at Sunesis Pharmaceuticals, Inc.
The center acts as a central research facility for scientists whose research would benefit from such technology. Its ultimate goal is to help pave the way for the discovery of new small molecules for research and potential therapeutics.
Small-molecule drugs – which target a specific protein or enzyme that modulates a biochemical or cellular process and have the potential to alter disease states – have traditionally been highly effective but are difficult to identify through standard, high-throughput screening.
QB3 is a cooperative effort among private industry and more than 200 scientists at UCSF, UC Berkeley and UC Santa Cruz. The institute harnesses the quantitative sciences of information technology, imaging and engineering to integrate and enhance scientific understanding of biological systems at all levels, enabling scientists to tackle problems that have been previously unapproachable. For more information, visit http://www.qb3.org.
Source: UCSF February 18, 2010
Sunday, February 14, 2010
Industry jobs at Liquidia and Regeneron
The company, which employs 46, will hire at least 10 new workers to prepare for human testing later this year.
Liquidia is currently hiring exceptional scientists and technicians to advance our multi-disciplinary research and development programs. For openings, please click here.
Regeneron, a midsized biotech company with facilities located near Albany, NY and NYC, is in a hiring boom and will be hiring over 50 research positions in the coming months, including postdoctoral researchers.
Click here to access to the openings.
Sunday, February 7, 2010
Pharmaceutical Industry Fellowships
Recruiting for Candidates Interested in the Following Career Opportunities:
- Academia: Research or Teaching Faculty
- Pharmaceutical Industry: Scientist, Manager (Drug Development, Project Management, Regulatory Science, Pharmacosurveillance)
- Government: FDA Reviewing Scientist, Project Manager
Overview: The clinical research fellowship emphasizes research training required to take a leadership position as faculty in academia or in the clinical research pharmaceutical industry. The fellow will complete rotations within the Campbell University Clinical Research Center and Industry partner PharmLinkFHI. Industry rotations may include regulatory, safety surveillance, project management and new product development. This joint fellowship is collocated at Campbell University Clinical Research in Morrisville, NC (Raleigh-Durham, RTP). Industry Partners: Novella Clinical (RTP), King Pharmaceuticals (RTP).
Objectives:
- Obtain skills to develop research protocols in the clinical investigation of new drugs and post approval studies.
- Obtain advanced training in biostatistics and methods of trial design.
- Learn scientific writing skills and submit research for publication.
- Collaborate with other team members on conducting and completing regulatory submissions for Phase I- IV trials.
- Publish and give seminars on scholarly activities and drug development issues.
- Integrate the fellow with ongoing clinical research activities to understand case report form design, management of data and statistical analysis.
Duration: One Year Fellowship. Fellowship Start Date: July 1, 2010.
Submit Early Applications (email or regular mail) by March 5, 2010:
1. A letter of interest
2. Resume/Curriculum Vitae
3. Transcripts (student photocopy is acceptable)
4. Names and address of three references.
For Further Information or to apply, contact:
Brenda Jamerson, PharmD
Associate Professor, Director Clinical Research Center
Campbell University School of Pharmacy
808 Aviation Parkway, Suite 1100
Morrisville, NC 27560
Email: jamerson@campbell.edu, Tel: 919-655-1263
Wednesday, February 3, 2010
Scientists find ideal target for malaria therapy
Two groups of Howard Hughes Medical Institute (HHMI) scientists working independently have identified a critical enzyme that allows the malaria-causing parasite, Plasmodium falciparum, to take over and thrive in human red blood cells.
The enzyme plasmepsin V (PMV) is a gatekeeper inside the malaria parasite that allows the parasite to export its own proteins into a human red blood cell. Once PMV opens the gate into the red blood cell, the parasite moves hundreds of the proteins into cell, which remodels it and, eventually, annihilates it. The new observations demonstrate that PMV is critical to survival of the malaria parasite and suggest that drugs targeting PMV may be able to kill the parasite before it develops inside red blood cells. This research was published by HHMI international research scholar Alan Cowman and HHMI investigator Daniel Goldberg in two articles in the February 4, 2010, issue of Nature.
You can watch the cool interactive movies at HHMI website about "The Life cycle of Malaria Part 1: Human Host and Part 2: Mosquito Host".
Monday, February 1, 2010
The New Drug Approvals of 2009
1. Savella - Forest Labs
2. Uloric - Takeda
3. Afinitor - Novartis
4. Coartem - Novartis
5. Ulesfia - Sciele Pharma
6. Simponi - Johnson & Johnson
7. Dysport - Ipsen, Medicis
8. Fanapt - Vanda Pharma
9. Samsca - Otsuka Pharma
10. Besivance - Bausch & Lomb
11. Ilaris - Novartis
12. Multaq - Sanofi-Aventis
13. Effient - Eli Lilly, Daiichi Sankyo
14. Onglyza - AstraZeneca, BMS
15. Livalo - Kowa Research
16. Saphris - Merck's Organon USA
17. Extavia - Novartis
18. Sabril - Lundbeck
19. Bepreve - Ista Pharma
20. Vibativ - Theravance, Astellas
21. Folotyn - Allos Therapeutics
22. Stelara - Johnson & Johnson
23. Votrient - GSK
24. Arzerra - GSK
25. Istodax - Gloucester Pharma
26. Kalbitor - Dyax Corp.
Subscribe to Posts [Atom]